Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more
Zydus Lifesciences Limited (ZYDUSLIFE) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2023: 0.018x
Based on the latest financial reports, Zydus Lifesciences Limited (ZYDUSLIFE) has a cash flow conversion efficiency ratio of 0.018x as of September 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₹3.68 Billion) by net assets (₹209.41 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zydus Lifesciences Limited - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Zydus Lifesciences Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Zydus Lifesciences Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zydus Lifesciences Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Haemonetics Corporation
NYSE:HAE
|
0.103x |
|
China Oilfield Services Limited
F:CO9
|
0.028x |
|
Reece Limited
OTCGREY:REECF
|
-0.010x |
|
Youngor Group Co Ltd
SHG:600177
|
0.020x |
|
Jb Financial
KO:175330
|
-0.001x |
|
NIPPON YUSEN K.K.SP.DR1/5
F:NYK
|
N/A |
|
Penske Automotive Group Inc
NYSE:PAG
|
0.055x |
|
Hangzhou Tigermed Consulting Co. Ltd
PINK:HNGZY
|
0.019x |
Annual Cash Flow Conversion Efficiency for Zydus Lifesciences Limited (2004–2025)
The table below shows the annual cash flow conversion efficiency of Zydus Lifesciences Limited from 2004 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | ₹263.58 Billion | ₹67.77 Billion | 0.257x | +77.78% |
| 2024-03-31 | ₹221.02 Billion | ₹31.96 Billion | 0.145x | +5.89% |
| 2023-03-31 | ₹196.88 Billion | ₹26.89 Billion | 0.137x | +23.67% |
| 2022-03-31 | ₹190.54 Billion | ₹21.04 Billion | 0.110x | -49.93% |
| 2021-03-31 | ₹149.30 Billion | ₹32.93 Billion | 0.221x | +3.10% |
| 2020-03-31 | ₹117.10 Billion | ₹25.05 Billion | 0.214x | -13.31% |
| 2019-03-31 | ₹116.79 Billion | ₹28.82 Billion | 0.247x | +139.88% |
| 2018-03-31 | ₹89.36 Billion | ₹9.19 Billion | 0.103x | -45.75% |
| 2017-03-31 | ₹71.16 Billion | ₹13.49 Billion | 0.190x | -47.81% |
| 2016-03-31 | ₹54.87 Billion | ₹19.94 Billion | 0.363x | +61.65% |
| 2015-03-31 | ₹44.20 Billion | ₹9.94 Billion | 0.225x | -9.20% |
| 2014-03-31 | ₹35.83 Billion | ₹8.87 Billion | 0.248x | +28.35% |
| 2013-03-31 | ₹30.64 Billion | ₹5.91 Billion | 0.193x | +2.37% |
| 2012-03-31 | ₹26.64 Billion | ₹5.02 Billion | 0.188x | -37.02% |
| 2011-03-31 | ₹22.38 Billion | ₹6.70 Billion | 0.299x | -21.11% |
| 2010-03-31 | ₹16.68 Billion | ₹6.32 Billion | 0.379x | +118.22% |
| 2009-03-31 | ₹12.58 Billion | ₹2.19 Billion | 0.174x | +1.43% |
| 2008-03-31 | ₹10.82 Billion | ₹1.85 Billion | 0.171x | -40.22% |
| 2007-03-31 | ₹8.80 Billion | ₹2.52 Billion | 0.287x | +80.46% |
| 2006-03-31 | ₹7.00 Billion | ₹1.11 Billion | 0.159x | -58.87% |
| 2005-03-31 | ₹5.93 Billion | ₹2.29 Billion | 0.386x | -11.46% |
| 2004-03-31 | ₹5.36 Billion | ₹2.34 Billion | 0.436x | -- |